Literature DB >> 2552505

Presentation of axillary lymphadenopathy without detectable breast primary (T0 N1b breast cancer): experience at Institut Curie.

F Campana1, A Fourquet, M A Ashby, X Sastre, D Jullien, P Schlienger, A Labib, J R Vilcoq.   

Abstract

Between 1960 and 1985, 31 patients presented to Institut Curie with isolated axillary lymphadenopathy, of probable metastatic origin from the breast, but without clinical or radiological evidence of a breast tumor and no other primary tumor. The mean age was 54.6 years (range 39-79 years). Histological diagnosis was obtained by axillary surgery (22 cases), drill biopsy (6 cases), and cytology (3 cases). All slides were reviewed for the present study. Treatment consisted of axillary surgery followed by radiotherapy in 22 patients, radiotherapy followed by axillary surgery in 6 patients, radiotherapy followed by modified radical mastectomy in one patient, and radiotherapy alone in 2 patients. Systemic adjuvant treatment was given to 11/31 patients. The median follow-up was 9 years (range 2-26 years). Eight recurrences have appeared. Four patients recurred in the breast only (mean time to relapse: 112 months, range 63-162 months). The four other patients recurred both in breast and/or axilla (mean time to relapse: 23 months, range 7-46 months). Nine patients have developed distant metastases, of whom three also had locoregional recurrence. Among the 11 patients who had had systemic treatment, 5/11 had recurrence or metastases. The overall 5 and 10 year actuarial survival rates were 76 and 71%, respectively. The metastasis-free 5 and 10 year actuarial survival rates were 73 and 71%, respectively. Axillary metastases without clinical or radiological evidence of a primary breast tumor represents a discrete clinical entity, the prognosis of which appears to be better than that of clinical invasive breast cancer with associated lymph node involvement.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2552505     DOI: 10.1016/0167-8140(89)90077-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  10 in total

Review 1.  Advances in breast imaging: magnetic resonance imaging.

Authors:  Lia Bartella; Elizabeth A Morris
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

2.  Oncologic Outcomes After Treatment for MRI Occult Breast Cancer (pT0N+).

Authors:  Damian P McCartan; Emily C Zabor; Monica Morrow; Kimberly J Van Zee; Mahmoud B El-Tamer
Journal:  Ann Surg Oncol       Date:  2017-07-12       Impact factor: 5.344

3.  Population-based analysis of occult primary breast cancer with axillary lymph node metastasis.

Authors:  Gary V Walker; Grace L Smith; George H Perkins; Julia L Oh; Wendy Woodward; Tse-Kuan Yu; Kelly K Hunt; Karen Hoffman; Eric A Strom; Thomas A Buchholz
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

4.  Carcinoma of Unknown Primary - an Orphan Disease?

Authors:  Alwin Krämer; Gerdt Hübner; Andreas Schneeweiss; Gunnar Folprecht; Kai Neben
Journal:  Breast Care (Basel)       Date:  2008-06-19       Impact factor: 2.860

5.  Retrospective study of women presenting with axillary metastases from occult breast carcinoma.

Authors:  D Kay Blanchard; David R Farley
Journal:  World J Surg       Date:  2004-06       Impact factor: 3.352

6.  A unique presentation of occult primary breast cancer with a review of the literature.

Authors:  Inaya Ahmed; Kavita Dharmarajan; Amy Tiersten; Ira Bleiweiss; Hank Schmidt; Sheryl Green; Richard L Bakst
Journal:  Case Rep Oncol Med       Date:  2015-03-18

7.  Survival outcomes of different treatment methods for the ipsilateral breast of occult breast cancer patients with axillary lymph node metastasis: a single center experience.

Authors:  Sang Min Woo; Byung Ho Son; Jong Won Lee; Hee Jeong Kim; Jong Han Yu; Beom Seok Ko; Guiyun Sohn; Yu Ra Lee; Hanna Kim; Sei Hyun Ahn; Seung Hee Baek
Journal:  J Breast Cancer       Date:  2013-12-31       Impact factor: 3.588

Review 8.  Occult breast cancer: Where are we at?

Authors:  Adam Ofri; Katrina Moore
Journal:  Breast       Date:  2020-10-27       Impact factor: 4.380

9.  Comparable Survival between Additional Radiotherapy and Local Surgery in Occult Breast Cancer after Axillary Lymph Node Dissection: A Population-based Analysis.

Authors:  San-Gang Wu; Wen-Wen Zhang; Jia-Yuan Sun; Feng-Yan Li; Huan-Xin Lin; Yong-Xiong Chen; Zhen-Yu He
Journal:  J Cancer       Date:  2017-10-17       Impact factor: 4.207

10.  Clinicopathological characteristics and treatment outcomes of occult breast cancer: a SEER population-based study.

Authors:  Li-Ping Ge; Xi-Yu Liu; Yi Xiao; Zong-Chao Gou; Shen Zhao; Yi-Zhou Jiang; Gen-Hong Di
Journal:  Cancer Manag Res       Date:  2018-10-09       Impact factor: 3.989

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.